1:38 PM
 | 
Jun 23, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DSMB recommends continuation of Galectin's Phase IIb NASH trial

Galectin Therapeutics Inc. (NASDAQ:GALT) said a DSMB recommended for the third time continuation of the Phase IIb NASH-CX trial evaluating galactoarabino-rhamnogalacturonate (GR-MD-02) in non-alcoholic steatohepatitis (NASH) patients with cirrhosis. Galectin said the DSMB found no safety concerns among the...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >